FASENRA SCEI for long-term use

Trial Identifier: D3250C00057
Sponsor: AstraZeneca
NCTID:: NCT03588546
Start Date: May 2018
Primary Completion Date: April 2025
Study Completion Date: April 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D3250C00057
Japan Akita, Japan, D3250C00057
Japan Aomori, Japan, D3250C00057
Japan Chiba, Japan, D3250C00057
Japan Ehime, Japan, D3250C00057
Japan Fukui, Japan, D3250C00057
Japan Fukuoka, Japan, D3250C00057
Japan Fukuoka, Japan
Japan Fukushima, Japan, D3250C00057
Japan Gifu, Japan, D3250C00057
Japan Gunma, Japan, D3250C00057
Japan Hiroshima, Japan, D3250C00057
Japan Hokkaido, Japan, D3250C00057
Japan Hyogo, Japan, D3250C00057
Japan Ibaraki, Japan, D3250C00057
Japan Ishikawa, Japan, D3250C00057
Japan Iwate, Japan, D3250C00057
Japan Kagawa, Japan, D3250C00057
Japan Kagoshima, Japan, D3250C00057
Japan Kanagawa, Japan, D3250C00057
Japan Kochi, Japan, D3250C00057
Japan Kumamoto, Japan, D3250C00057
Japan Kyoto, Japan, D3250C00057
Japan Mie, Japan, D3250C00057
Japan Miyagi, Japan, D3250C00057
Japan Nagano, Japan, D3250C00057
Japan Nagasaki, Japan, D3250C00057
Japan Nara, Japan, D3250C00057
Japan Niigata, Japan, D3250C00057
Japan Oita, Japan, D3250C00057
Japan Okayama, Japan, D3250C00057
Japan Okinawa, Japan, D3250C00057
Japan Osaka, Japan, D3250C00057
Japan Saitama, Japan, D3250C00057
Japan Shiga, Japan, D3250C00057
Japan Shimane, Japan, D3250C00057
Japan Shizuoka, Japan, D3250C00057
Japan Tochigi, Japan, D3250C00057
Japan Tokushima, Japan, D3250C00057
Japan Tokyo, Japan, D3250C00057
Japan Tottori, Japan, D3250C00057
Japan Toyama, Japan, D3250C00057
Japan Wakayama, Japan, D3250C00057
Japan Yamagata, Japan, D3250C00057
Japan Yamaguchi, Japan, D3250C00057
Japan Yamanashi, Japan, D3250C00057